Study shows how novel drug screen can personalise cancer therapy
A screening method called dynamic BH3 profiling can identify potentially effective combinations of existing drugs for personalised cancer therapy, research has shown.
List view / Grid view
A screening method called dynamic BH3 profiling can identify potentially effective combinations of existing drugs for personalised cancer therapy, research has shown.
Drug molecules from pine and spruce trees can affect certain ion channels and had antiseizure effects in pre-clinical studies.
Scientists have found four clinically approved drugs and nine compounds with the potential to be repurposed as therapeutics for COVID-19.
The experimental drug TEMPOL has demonstrated antiviral activity against COVID-19 in a pre-clinical study in cell cultures.
Scientists have developed an implant that releases insulin-secreting cells which has shown success at treating diabetes in mice.
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
Analysis of one million SARS-CoV-2 genome sequences has revealed a new variant named T478K, spreading mostly in Mexico.
Antibodies produced by B cells against the H1N1 influenza virus can also neutralise other strains, which could be used to developed vaccines.
Scientists have discovered that hepatic stellate cells are key in allowing dormant cancer cells to awaken and form fatal metastases.
A new high-throughput screening platform has been used to identify two compounds with antiviral activity against the Nipah and Hendra viruses.
A new method named scifi-RNA-seq marks the RNA of cells with specific barcodes, enabling the sequencing of many cells at the same time.
Scientists have created a RT-ddPCR assay to analyse both the non-coding and coding RNA regions of SARS-CoV-2.
A new non-invasive microscopic fluorescence imaging method has been developed to reveal details of the brain in animal models of various diseases.
A new DNA vaccine encoding the SARS-CoV-2 Spike protein has shown promise at protecting mice and hamsters against COVID-19.
A modified luciferase enzyme has been developed as an immunosensor to be fused with a Q-body and used in immunoassays.